(NasdaqGM:ALT), Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and metabolic diseases, today announced a CEO […]
(NASDAQ:MDCX), PHILADELPHIA, Dec. 01, 2025 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that Carolyn Bonner, currently President of the Company, has also been appointed Chief Financial Officer, effective
(TSX-V – NEX Board:HC),(OTC US:HCNWF),(OtherOTC:HCNWF), Recognized Revenue of $3.7 Million, Up $2.3 Million Year-Over-Year Gross Profit of $0.9 Million, Up $0.4 Million Year-Over-Year Net and Comprehensive Loss Reduced by 63% Year-Over-Year Delivered 319 New Charging Ports, Including 48 DC Fast Charging Ports VANCOUVER, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) — Hypercharge Networks Corp. (TSXV:
(NASDAQ:CGTX), – Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting –– Actively Evaluating Strategy Across DLB and Alzheimer's Disease – PURCHASE, N.Y., Dec. 01, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented plans for a registrational program
(TSX:BBD-A),(TSX:BBD-B),(OTC US:BDRBF),(Other OTC:BDRBF), MONTREAL, Dec. 01, 2025 (GLOBE NEWSWIRE) — The Bombardier team is proud to share that Moody's has upgraded the company's credit rating from B1 to Ba3, with a positive outlook. With this recent upgrade, Bombardier's credit ratings are back in the Ba/BB category with both Moody's and S&P for the first time
(NASDAQ:BIIB),(NASDAQ:STOK), CAMBRIDGE, Mass and BEDFORD, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced data presentations from studies of zorevunersen at the 2025 American Epilepsy Society (AES) Annual Meeting,
(NASDAQ:SYBT), LOUISVILLE, Ky., Dec. 01, 2025 (GLOBE NEWSWIRE) — Rick Seadler has joined Stock Yards Bank & Trust as its Bowling Green Market President. Prior to joining the bank, Seadler served as the Regional President at Pinnacle Financial Partners in Bowling Green. With more than 35 years of banking experience, he has also held leadership
(NASDAQ:ABEO), CLEVELAND, Dec. 01, 2025 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On November 30, 2025, the Compensation Committee of Abeona's Board of Directors granted restricted stock
(NASDAQ:PSTV), HOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the acceptance of an abstract for poster spotlight (with oral) presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), being held
(NasdaqGM:NEXN), NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) — Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced the Company repurchased 427,500 Ordinary Shares at an average price of $7.11 during November 2025. As of November 30, 2025, Nexxen